DCOY Decoy Therapeutics Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1615219 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-231.0%
TTM EPS YoY118.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-11,102.9%
ROA-222.5%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets48.3%
Debt / equity0.00x
Current ratio1.97x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.56x
Accruals ratio-98.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $307,430 | $227,629 | — | — | $0 | $0 | — | — |
| R&D expense | $1.57M | $1.30M | $749,813 | $114,429 | $61,826 | $116,383 | $75,532 | $175,344 |
| SG&A expense | $1.75M | $1.33M | $1.53M | $402,167 | $833,304 | $849,182 | $1.64M | $1.31M |
| Operating income | -$3.01M | -$2.63M | -$2.28M | -$9.03M | -$895,130 | -$965,565 | -$1.72M | -$1.49M |
| Net income | -$2.99M | -$2.37M | -$2.22M | -$8.98M | -$873,467 | -$957,825 | -$1.71M | -$1.46M |
| EBITDA | -$2.99M | -$2.62M | -$2.28M | -$9.03M | -$894,024 | -$964,459 | -$1.72M | -$1.49M |
| EPS (basic) | -3.53 | -4.46 | -4.18 | — | -21.76 | -81.21 | -240.07 | — |
| EPS (diluted) | -3.53 | -4.46 | -4.18 | — | -21.76 | -81.21 | -240.07 | — |
| Weighted avg. shares (diluted) | 845,439 | 531,968 | 531,968 | — | 40,132 | 11,794 | 7,121 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $8.17M | $8.29M | $7.82M | $10.71M | $4.81M | $794,886 | $1.80M | $2.43M |
| Current assets | $8.38M | $8.57M | $8.36M | $10.99M | $6.06M | $1.36M | $2.31M | $2.99M |
| PP&E, net | $385,118 | $399,077 | $35,741 | $40,559 | — | — | — | $0 |
| Total assets | $8.79M | $9.00M | $8.42M | $11.06M | $6.10M | $1.39M | $2.34M | $3.02M |
| Current liabilities | $4.25M | $4.68M | $4.55M | $5.17M | — | — | — | $1.51M |
| Total liabilities | $4.25M | $4.68M | $4.55M | $5.17M | $1.85M | $2.22M | $2.28M | $1.51M |
| Shareholders' equity | $4.55M | $4.32M | $3.88M | $5.89M | -$4.25M | -$829,724 | $61,866 | $1.51M |
| Shares outstanding | 2.39M | 531,968 | 531,968 | 531,968 | 944,491 | 2.13M | 2.08M | 96,077 |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.59M | -$2.65M | -$2.89M | -$1.14M | -$1.65M | -$862,297 | -$1.18M | -$742,518 |
| Investing cash flow | -$79,366 | — | — | $964,735 | -$200,000 | — | — | $0 |
| Financing cash flow | $2.55M | $3.16M | $0 | $6.07M | $5.86M | -$141,197 | $545,566 | -$106,983 |
| Depreciation & amortization | $24,863 | $13,632 | $5,924 | $3,833 | $1,106 | $1,106 | $1,106 | $1,106 |
| Stock-based compensation | $253,474 | $206,177 | $213,044 | $139,523 | $22,846 | $23,155 | $33,534 | $51,045 |
Free plan shows the latest 8 periods; Pro shows all 50 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.